Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) reported on Thursday that its partner Eisai Co Ltd (TYO:4523) projects Leqembi (lecanemab) revenue to reach JPY76.5bn (approximately SEK5.1bn) for fiscal year 2025 (April 2025-March 2026), representing a 73% increase over the prior year.

This is expected to generate approximately SEK510m in royalty income for BioArctic during the same period.

Eisai leads the global development, regulatory and commercialisation of Leqembi, in collaboration with Biogen, and retains final decision-making authority. In the Nordic region, BioArctic and Eisai are preparing for joint commercialization efforts.

Leqembi (lecanemab) is a monoclonal antibody targeting aggregated forms of amyloid-beta and is approved in the United States, European Union, Japan, China, Great Britain and other markets for early-stage Alzheimer's disease.

These approvals are primarily based on positive Phase 3 results from Eisai's Clarity AD trial, which demonstrated statistically significant outcomes across all endpoints. Eisai continues to pursue regulatory expansion, with additional submissions underway.

In January 2025, US regulators approved a supplemental Biologics License Application for intravenous maintenance dosing, and a Biologics License Application for a subcutaneous autoinjector is under FDA review, with a PDUFA date set for 31 August 2025.

BioArctic will release its Q1 2025 financial results on 21 May.